Spironolactone Dosing Guidelines

Maximum Doses by Clinical Indication

The European Society of Cardiology recommends a target dose of 50 mg once daily for chronic heart failure management, which represents the evidence-based maximum for this indication 1
For cirrhosis with ascites, the maximum dose is 400 mg/day, typically combined with furosemide 160 mg/day in a 100:40 mg ratio, as recommended by the American Association for the Study of Liver Diseases 2
The American Heart Association recommends a maximum dose of 100 mg/day for essential hypertension, as doses greater than this generally do not provide additional blood pressure reductions is not cited, however, the maximum dose for primary hyperaldosteronism is 400 mg/day 2

For moderate renal dysfunction (eGFR 30-50 mL/min/1.73 m²), the American College of Cardiology recommends initiating at 25 mg every other day due to increased hyperkalemia risk 3
Spironolactone is contraindicated in patients with severe renal dysfunction (eGFR <30 mL/min/1.73 m²), as recommended by the National Kidney Foundation 3
The European Renal Association recommends not initiating spironolactone if baseline creatinine exceeds 2.5 mg/dL in men or 2.0 mg/dL in women 3

If potassium rises to >5.5 mmol/L, the European Society of Cardiology recommends halving the dose (e.g., 25 mg on alternate days) and monitoring blood chemistry closely 1
If potassium rises to ≥6.0 mmol/L, the American Heart Association recommends stopping spironolactone immediately and monitoring blood chemistry closely; specific treatment of hyperkalemia may be needed 1

The European Society of Cardiology recommends checking renal function and serum electrolytes before starting spironolactone, and rechecking at 1 and 4 weeks after starting treatment or any dose change 1
The American College of Cardiology recommends monitoring at 1, 2, 3, and 6 months, then every 6 months thereafter, for patients on maintenance dose 1

The American College of Cardiology warns that spironolactone-induced hyperkalemia and renal insufficiency are more common in clinical practice than reported in trials, and recommends careful monitoring 3
The European Society of Cardiology recommends never combining ACE inhibitor + ARB + aldosterone antagonist routinely, as this dramatically increases hyperkalemia and renal dysfunction risk 3